Immunogenicity and safety of Pentaxim [Hib-DTaP-poliovirus vaccine] as 3 doses primary vaccination followed by a booster dose at 18 months.
Phase of Trial: Phase III
Latest Information Update: 16 Apr 2013
At a glance
- Drugs Hib-DTaP-poliovirus vaccine (Primary) ; DTaP vaccine; Hib vaccine conjugate; Poliovirus vaccine inactivated
- Indications Diphtheria; Haemophilus infections; Pertussis; Poliomyelitis; Tetanus
- Focus Pharmacodynamics
- Sponsors Sanofi
- 16 Feb 2010 Actual number of patients added to 792 as reported by ClinicalTrials.gov.
- 16 Feb 2010 Actual end date added to 1 Jun 2009 as reported by ClinicalTrials.gov.
- 16 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.